What questions should I ask a patient receiving medication‑assisted treatment (MAT) for substance use disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Essential Questions for Patients on Medication-Assisted Treatment (MAT)

When evaluating a patient on MAT for substance use disorder, systematically assess medication adherence, substance use patterns, withdrawal symptoms, side effects, psychosocial functioning, and comorbid conditions to optimize treatment outcomes and prevent relapse or overdose.

Core Assessment Domains

1. Medication Adherence and Effectiveness

  • Are you taking your medication as prescribed? (dose, timing, route)
  • When was your last dose?
  • Are you experiencing cravings? If yes, rate intensity (0-10 scale)
  • Is the medication controlling your withdrawal symptoms?
  • Any missed doses in the past week/month? If yes, explore barriers

This directly impacts mortality risk, as consistent MAT adherence reduces overdose death by maintaining opioid receptor occupancy and preventing return to illicit use 1.

2. Current Substance Use Status

  • Have you used any opioids (or other substances) since your last visit?
  • What substances? How much? How often? Route of administration?
  • Last use date and circumstances?
  • Are you using alcohol, benzodiazepines, or other sedatives? (critical for overdose risk assessment)

Be direct and non-judgmental. Patients who relapse need dose adjustment or intensified support, not punishment 2. The motivational interviewing approach—asking "what concerns you about your substance use?"—yields more honest responses than confrontational questioning 2.

3. Withdrawal and Side Effects

  • Any withdrawal symptoms? (sweating, nausea, muscle aches, anxiety, insomnia)
  • Medication side effects? (constipation, sedation, headache, sleep disturbance)
  • Any precipitated withdrawal? (especially relevant for buprenorphine timing)

Side effects like constipation are common but manageable; untreated side effects drive non-adherence 1.

4. Diversion and Misuse Risk

  • How are you storing your medication safely?
  • Has anyone asked you for your medication?
  • Are you taking it as prescribed (sublingual for buprenorphine, not crushing/injecting)?

This is particularly important for buprenorphine, though the buprenorphine/naloxone formulation reduces diversion risk 1.

5. Psychosocial Functioning and Recovery

  • How is your mood? Screen for depression and anxiety
  • Sleep quality?
  • Are you attending counseling or support groups? (frequency, perceived benefit)
  • Employment/school status?
  • Housing stability?
  • Social support system?

MAT works best when combined with psychosocial support, though medication alone is superior to counseling alone for opioid use disorder 1. Unstable housing may favor naltrexone over agonist therapy 1.

6. Comorbid Conditions

  • Screen for co-occurring mental health disorders (depression, anxiety, PTSD, bipolar disorder)
  • Intimate partner violence screening (common in this population 2)
  • Infectious disease risk: IV drug use history, hepatitis C, HIV, endocarditis symptoms 1
  • Chronic pain assessment if relevant

Mental health comorbidity is the rule, not the exception—70% of patients with SUDs in treatment programs receive psychiatric medications 1.

7. Treatment Goals and Motivation

  • What are your goals for treatment?
  • How long do you plan to stay on MAT? (address misconceptions about "short-term" treatment)
  • What would help you stay in treatment?

Longer-term maintenance treatment is indicated; brief tapers lead to high relapse rates 2. Patient perspectives on treatment duration vary widely and require shared decision-making 3.

8. Safety Planning

  • Do you have naloxone at home? If not, prescribe it
  • Does someone close to you know how to use it?
  • Are you ever alone when using substances?

Critical Red Flags Requiring Immediate Action

  • Concurrent benzodiazepine or alcohol use (dramatically increases overdose risk)
  • IV drug use (assess for endocarditis, abscess, hepatitis C)
  • Suicidal ideation
  • Precipitated withdrawal symptoms (may need dose adjustment)
  • Diversion or selling medication
  • Pregnancy (requires specialized MAT management)

Common Pitfalls to Avoid

Don't assume relapse means treatment failure. Opioid use disorder is a chronic relapsing condition; adjust treatment intensity rather than discharge the patient 1. Brief lapses are common and should trigger enhanced support, not punitive measures.

Don't neglect the "assisted" part of MAT. While medication is the most critical component for opioid use disorder, psychosocial support improves retention and outcomes 1.

Don't use confrontational communication. Motivational interviewing techniques—eliciting the patient's own concerns and goals—are more effective than telling patients what they "need" to do 2.

Don't forget age-specific considerations. For adolescents, buprenorphine is FDA-approved for ages 16+, but methadone programs typically cannot admit patients under 18 1.

Documentation Priorities

Document substance use patterns, medication adherence, side effects, psychosocial functioning, and any dose adjustments. This creates a longitudinal record that informs treatment decisions and demonstrates medical necessity for continued MAT, which some patients may need indefinitely given the chronic nature of severe opioid use disorder 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.